A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

March 31, 2028

Conditions
Lymphocytic Leukemia
Interventions
DRUG

NeoVax

It stimulates the immune system to attack cancer cells.

DRUG

Cyclophosphamide

It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.

DRUG

Pembrolizumab

Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Oncovir, Inc.

INDUSTRY

collaborator

BioNTech SE

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER